¼¼°èÀÇ ³»ºÐºñ Ä¡·áÁ¦ ½ÃÀå(2025-2029³â)
Global Endocrinology Drugs Market 2025-2029
»óǰÄÚµå : 1692980
¸®¼­Ä¡»ç : TechNavio
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 205 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,500 £Ü 3,463,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,000 £Ü 5,541,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

³»ºÐºñ Ä¡·áÁ¦ ½ÃÀåÀº 2024-2029³â 7.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 2024-2029³â 401¾ï 4,410¸¸ ´Þ·¯ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼¼°èÀÇ ³»ºÐºñ Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, 25°³ º¥´õ¿¡ ´ëÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

ÇöÀçÀÇ ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ¼ºÀå¿äÀÎ, ½ÃÀå ȯ°æ Àü¹Ý¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ³»ºÐºñ ÁúȯÀÇ À¯º´·ü Áõ°¡, À¯¸ÁÇÑ ³»ºÐºñÇÐ ÆÄÀÌÇÁ¶óÀÎ, »õ·Î¿î Á¦Çü ¹× ¾à¹° Àü´Þ ½Ã½ºÅÛ ¿¬±¸ µîÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ 2025³â
Á¾·á ¿¬µµ 2029³â
¿¹Ãø ±â°£ 2025-2029³â
¼ºÀå ¸ð¸àÅÒ °¡¼Ó
YOY 2025 7%
CAGR 7.6%
Áõ°¡¾× 401¾ï 4,410¸¸ ´Þ·¯

ÀÌ Á¶»ç´Â ¾÷°è ÁÖ¿ä Âü°¡ÀÚÀÇ ÀǰßÀ» Æ÷ÇÔÇÏ¿© 1Â÷ ¹× 2Â÷ Á¤º¸¸¦ °´°üÀûÀ¸·Î °áÇÕÇÏ¿© ¼öÇàµÇ¾ú½À´Ï´Ù. º¸°í¼­¿¡´Â ÁÖ¿ä ±â¾÷ ºÐ¼®, Á¾ÇÕÀûÀÎ ½ÃÀå ±Ô¸ð µ¥ÀÌÅÍ, Áö¿ª ºÐ¼®¿¡ µû¸¥ ºÎ¹®, °ø±Þ¾÷ü ÇöȲÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. º¸°í¼­¿¡´Â °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅͰ¡ ÀÖ½À´Ï´Ù.

º» Á¶»ç´Â ÇâÈÄ ¸î ³â µ¿¾È ³»ºÐºñ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ÀÌÀ¯ Áß Çϳª·Î ºñ¸¸°ú ³»ºÐºñ ÁúȯÀÇ ¿¬°ü¼ºÀ» ²Å¾Ò½À´Ï´Ù. ¶ÇÇÑ, ³»ºÐºñ Áúȯ¿¡ ´ëÇÑ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ »ç¿ë°ú ³ë·É Àα¸ Áõ°¡´Â ½ÃÀåÀÇ Å« ¼ö¿ä·Î À̾îÁú °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå Technavio ºÐ¼®

Á¦3Àå ½ÃÀå ±¸µµ

Á¦4Àå ½ÃÀå ±Ô¸ð

Á¦5Àå ½ÃÀå ±Ô¸ð ½ÇÀû

Á¦6Àå Á¤¼º ºÐ¼®

Á¦7Àå Five Forces ºÐ¼®

Á¦8Àå ½ÃÀå ¼¼ºÐÈ­ : Ä¡·á ¿µ¿ªº°

Á¦9Àå ½ÃÀå ¼¼ºÐÈ­ : À¯Åë ä³Îº°

Á¦10Àå °í°´ »óȲ

Á¦11Àå Áö¿ªº° »óȲ

Á¦12Àå ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ ¹× ¼ºÀå ¾ïÁ¦¿äÀÎ

Á¦13Àå °æÀï ±¸µµ

Á¦14Àå °æÀï ºÐ¼®

Á¦15Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The endocrinology drugs market is forecasted to grow by USD 40144.1 million during 2024-2029, accelerating at a CAGR of 7.6% during the forecast period. The report on the endocrinology drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increase in incidence of endocrine disorders, promising pipeline for endocrinology, and research in novel dosage formulations and drug delivery systems.

Market Scope
Base Year2025
End Year2029
Series Year2025-2029
Growth MomentumAccelerate
YOY 20257%
CAGR7.6%
Incremental Value$40144.1 mn

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's endocrinology drugs market is segmented as below:

By Therapy Area

By Distribution Channel

By Geographical Landscape

This study identifies the association between obesity and endocrine disorders as one of the prime reasons driving the endocrinology drugs market growth during the next few years. Also, use of biosimilars for endocrine disorders and growing geriatric population will lead to sizable demand in the market.

The report on the endocrinology drugs market covers the following areas:

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading endocrinology drugs market vendors that include Abbott Laboratories, Acerus Pharmaceuticals Corp., Ascendis Pharma AS, Bayer AG, Beta Cell NV, Biocon Ltd., Eli Lilly and Co., Endo International PLC, F. Hoffmann La Roche Ltd., GlaxoSmithKline PLC, Hanmi Pharm Co. Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and VeroScience LLC. Also, the endocrinology drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

2 Technavio Analysis

3 Market Landscape

4 Market Sizing

5 Historic Market Size

6 Qualitative Analysis

7 Five Forces Analysis

8 Market Segmentation by Therapy Area

9 Market Segmentation by Distribution Channel

10 Customer Landscape

11 Geographic Landscape

12 Drivers, Challenges, and Opportunity/Restraints

13 Competitive Landscape

14 Competitive Analysis

15 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â